SCHEMBL16634930

SCHEMBL16634930

CC(C)(O)CC(=O)N1CCN(Cc2ccc3c(c2)CCN(C(=O)O)C3)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.44
HSP90AA1 P07900 2/20 0.41
HSP90AB1 P08238 2/20 0.41
CHEK1 O14757 5/20 0.40
FLT3 P36888 5/20 0.40
DPP8 Q6V1X1 1/20 0.40
HSP90B1 P14625 1/20 0.40
NAMPT P43490 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAP3K7 O43318 1/20 0.39
KIT P10721 1/20 0.39
RPS6KB1 P23443 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
KCNH2 Q12809 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16645225 0.88 ESR2 (0.56) FAAHHSP90AA1HSP90AB1CHEK1FLT3
SCHEMBL16645227 0.80 FAAH (0.42) FAAHLMNASMN1; SMN2CYP2C9ALDH1A1
SCHEMBL17969237 0.80 TSHR (0.47) FAAHDPP8NAMPTLMNASMN1; SMN2
SCHEMBL17969253 0.79 NAMPT (0.64) CHEK1FLT3NAMPTLMNASMN1; SMN2
SCHEMBL17969233 0.77 NAMPT (0.44) FAAHDPP8NAMPTLMNASMN1; SMN2
SCHEMBL13097367 0.75 ESR2 (0.62) CHEK1FLT3MAP3K7KITRPS6KB1
SCHEMBL4557635 0.75 HSP90AA1 (0.62) FAAHHSP90AA1HSP90AB1HSP90B1NAMPT
SCHEMBL16634812 0.74 CYP2C19 (0.48) FAAHLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL30575087 0.74 ABHD6 (0.53) CHEK1FLT3DPP8SMN1; SMN2MAP3K7
SCHEMBL31013967 0.73 ESR2 (0.63) FAAHHSP90AA1HSP90AB1HSP90B1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055304-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS Eli Lilly and Company (US) 2016-08-17 EP disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT FAAH 2036/4885HSP90AA1 2158/4885HSP90AB1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.